Scott T. Tagawa, M.D., MS, FACP, FASCO

Dr. Bashir Al Hussein is a Urologic Oncologist and Assistant Professor of Urology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. He completed his urology residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a Society of Urologic Oncology (SUO) fellowship at Vanderbilt University Medical Center. He also holds a Master of Public Health in Epidemiology from Vanderbilt University and earned his medical degree from the University of Jordan in Amman.Dr. Al Hussein is a urologic cancer surgeon who specializes in the diagnosis and management of genitourinary malignancies, including prostate, kidney, bladder, testicular, and penile cancers. He provides comprehensive cancer care using both robotic and open surgical approaches, tailored to the complexity and stage of each patient’s disease. His expertise includes minimally invasive robotic procedures—such as radical prostatectomy, partial nephrectomy, and cystectomy—as well as complex open operations for advanced or anatomically challenging tumors.Dr. Al Hussein’s research focuses on applying epidemiologic methods to improve the quality of cancer care, with an emphasis on decision-making, survivorship, and health literacy. His work has been published in leading journals, including The Journal of the American Medical Association (JAMA), The New England Journal of Medicine, and JAMA Internal Medicine. He is a recipient of the American Urological Association Research Scholar Award and serves as Director of the Adult Urology Clinic within the Department of Urology at Weill Cornell Medicine.NewsMost Men With Low-Risk Prostate Cancers Now Forgo Immediate Surgeryhttps://www.usnews.com/news/health-news/articles/2023-04-04/most-men-with-low-risk-prostate-cancers-now-forgo-immediate-surgeryDecade-Long Study Offers Guidance on Treatments for Prostate Cancerhttps://www.usnews.com/news/health-news/articles/2024-01-24/decade-long-study-offers-guidance-on-treatments-for-prostate-cancerInsights into adverse effects may help guide prostate cancer treatment decision-makinghttps://www.healio.com/news/hematology-oncology/20240227/insights-into-adverse-effects-may-help-guide-prostate-cancer-treatment-decisionmakingComparing Side Effects of Prostate Cancer Treatmentshttps://newsinhealth.nih.gov/2024/04/comparing-side-effects-prostate-cancer-treatmentsMore U.S. Prostate Cancer Patients Choosing Active Surveillancehttps://www.newswise.com/articles/more-u-s-prostate-cancer-patients-choosing-active-surveillance2More Men Choose Active Surveillance for Prostate Cancerhttps://www.newsmax.com/health/health-news/prostate-cancer-low-risk/2023/04/05/id/1115105/More men with prostate cancer opting for active surveillancehttps://www.healio.com/news/hematology-oncology/20230403/more-men-with-prostate-cancer-opting-for-active-surveillancehttps://www.usatoday.com/story/news/health/2024/01/24/prostate-cancer-treatment-study/72336323007/10-year study evaluates prostate cancer treatments, side effectshttps://www.msn.com/en-us/health/other/10-year-study-evaluates-prostate-cancer-treatments-side-effects/ar-BB1hc5v7Understanding Functional Outcomes in Prostate Cancerhttps://www.medscape.com/s/viewarticle/understanding-functional-outcomes-prostate-cancer-2024a10001t2?src=rssTreatment Adverse Events Vary With Favorable, Unfavorable Prognosis in Prostate Cancerhttps://www.physiciansweekly.com/treatment-adverse-events-vary-with-favorable-unfavorable-prognosis-in-prostate-cancer/Cory Booker didn’t go to the bathroom for 25 hours. Is that … OK?https://www.theguardian.com/wellness/2025/apr/03/how-long-without-peeing-is-bad

Dr. Saya Segal is a urogynecologist who specializes in the care of women with pelvic floor weakness resulting in conditions such as pelvic organ prolapse and bladder dysfunction. The network of pelvic structures which normally support a woman's uterus, bladder and rectum may weaken with progressing age, childbirth, obesity and other factors resulting in conditions such as cystocele, rectocele, uterine prolapse, urinary and fecal incontinence, bladder dysfunction and defecatory dysfunction.Dr. Segal offers comprehensive care for women with the above conditions. Together with the Weill Cornell Medicine physicians in the Division of Urogynecology in Obstetrics and Gynecology, Dr. Segal's patient treatment modalities include robotic, abdominal, and vaginal reconstructive surgery as well as medical and surgical treatment for urinary incontinence that span across a range of clinical options from guided pelvic muscle exercise to surgery for stress and/or urgency urinary incontinence. She also offers conservative management treatment options, such as in- office treatment for overactive bladder, and in office diagnostic procedures, like urodynamics and cystoscopy.Dr. Segal, who is trained as both a physician and an epidemiologist, has conducted extensive research aimed at improving outcomes for women with urogynecology issues. She has studied pelvic floor disorders in women across the age spectrum, and compared the outcomes of surgical versus conservative treatments for pelvic floor disorders.Dr. Segal is board certified in Obstetrics and Gynecology and Female Pelvic Medicine and Reconstructive Surgery. She received her undergraduate degree from the University of Texas at Austin, a Masters of Science in Clinical Epidemiology from the University of Pennsylvania, and her medical degree from the University of Texas Southwestern Medical School. After completing Obstetrics and Gynecology residency at New York University Medical Center, she completed an accredited three year fellowship in Urogynecology and Female Pelvic Medicine and Reconstructive Surgery at the University of Pennsylvania. Dr. Segal joined NewYork-Presbyterian, Weill Cornell Medicine in 2017 as an Assistant Professor of Obstetrics and Gynecology. Prior to joining Weill Cornell Medicine, Dr. Segal worked in the Division of Female Pelvic Medicine and Reconstructive Surgery at Rutgers-Robert Wood Johnson Medical School.

Encouse Golden, M.D., Ph.D., is a radiation oncologist specializing in gastrointestinal and lung cancers, with a focus on integrating cancer immunity into clinical management. As the Medical Director of Clinical Research at Weill Cornell Medicine's Department of Radiation Oncology, Dr. Golden is dedicated to advancing innovative treatment strategies that combine radiotherapy with immunotherapy. Dr. Golden's extensive research has demonstrated the potential of local radiotherapy to enhance antitumor immunity, establishing it as a powerful adjunct to immunotherapy. He is recognized for his contributions to the field, receiving multiple awards and certifications, and serves as an Associate Professor at Weill Cornell Medical College. Generated from the website